Form 4: Sangamo Therapeutics Director Margaret Horn Reports Acquisition of Shares and Stock Options

Director Margaret Horn reports acquisition of 25,000 shares of common stock, 50,000 stock options, and disposition of shares.

Summary

• On June 4, 2024, Margaret Horn, a director of Sangamo Therapeutics, reported acquiring 25,000 shares of common stock and 50,000 stock options.
• The 25,000 shares were acquired through a restricted stock unit (RSU) grant that will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders.
• Horn also acquired 50,000 stock options with an exercise price of $0.5676, exercisable immediately but subject to repurchase rights by the issuer.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date.
• Following these transactions, Horn beneficially owns 57,650 shares of Sangamo Therapeutics common stock and 50,000 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a positive sign, but it's not definitive.

Positives

• Acquisition of shares and stock options by a director may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal.

Key Dates